LICENSE AND CO-DEVELOPMENT AGREEMENT BY AND BETWEEN GENZYME CORPORATION AND ISIS PHARMACEUTICALS, INC. June 24, 2008License and Co-Development Agreement • August 11th, 2008 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Co-Development Agreement (together with all Exhibits, Schedules and other attachments hereto, this “Agreement”), is dated as of the 24th day of June, 2008 (the “Execution Date”), by and between Genzyme Corporation, a Massachusetts corporation (“Genzyme”) and Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis”). Genzyme and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN GLAXO GROUP LIMITED AND REGULUS THERAPEUTICS LLCProduct Development and Commercialization Agreement • August 11th, 2008 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases
